Update on prevalence and treatment of methicillin-resistant staphylococcus aureus infections

Expert Review of Anti-Infective Therapy

Volumn 5, Issue 6, 2007, Pages 961-981

  Loffler, Cindy A ^a   MacDougall, Conan ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ceftopibrole; Daptomycin; Glycopeptides; Linezolid; Methicillin resistant Staphylococcus aureus; Pharmacotherapy; Prevalence; Vancomycin

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFTOBIPROLE; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MACROLIDE; METICILLIN; MINOCYCLINE; NAFCILLIN; ORITAVANCIN; OXACILLIN; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELAVANCIN; TETRACYCLINE; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ANOREXIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL PNEUMONIA; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CATHETER INFECTION; CLINICAL TRIAL; COMMUNITY CARE; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ESOPHAGITIS; FLUSHING; GASTROINTESTINAL INFECTION; GEOGRAPHIC DISTRIBUTION; HEALTH CARE SYSTEM; HOSPITAL INFECTION; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY FAILURE; LACTIC ACIDOSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MYOPATHY; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OPTIC NEURITIS; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHOTOSENSITIVITY; PREVALENCE; PRURITUS; RESPIRATORY TRACT DISEASE; REVIEW; RHABDOMYOLYSIS; SEROTONIN SYNDROME; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; STEVENS JOHNSON SYNDROME; SUPERINFECTION; TASTE DISORDER; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VOMITING;

ACETAMIDES; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CLINDAMYCIN; DAPTOMYCIN; DOXYCYCLINE; FOLIC ACID ANTAGONISTS; GLYCOPEPTIDES; HUMANS; METHICILLIN; METHICILLIN RESISTANCE; MINOCYCLINE; OXAZOLIDINONES; PREVALENCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SULFAMETHOXAZOLE; TEICOPLANIN; TRIMETHOPRIM; VANCOMYCIN; WORLD HEALTH;

EID: 37349069550     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.5.6.961     Document Type: Review

References (144)

1. Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn. Microbiol. Infect. Dis. 52(2), 113-122 (2005).
2. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin. Infect. Dis. 36(1), 53-59 (2003).
3. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphyloccus aureus bacteremia on patient outcomes: mortality length of stay, and hospital charges. Infect. Control Hosp. Epidemiol. 26(2), 166-174 (2005).
4. Shurland S, Zhan M, Bradham DD, Roghmann MC. Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Infect. Control Hosp. Epidemiol. 28(3), 273-279 (2007).
5. Engemann JJ, Carmeli Y, Cosgrove SE et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin. Infect. Dis. 36(5), 592-598 (2003).
6. Chang FY, Peacock JE Jr, Musher DM et al. Staphylococcus aureaus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine 82(5), 333-339 (2003).
7. Deurenberg RH, Vink C, Kalenic S, Friedrich AW, Bruggeman CA, Stobberingh EE. The molecular evolution of methicillin-resistant Staphylococcus aurrus. Clin. Microbiol. Infect. 13(3), 222-235 (2007).
8. Chambers HF. Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clinical Microbiology Reviews, 10(4), 781-791 (1997).
9. Tristan A, Ferry T, Durand G et al. Virulence determinants in community and hospital meticillin-resistant Stapbylocccus aureus. J Hasp. Infect. 65 (Suppl. 2), 105-109 (2007).
10. Klevens RM, Edwards JR, Tenover FC, McDonald LC, Horan T, Gaynes R. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin. Infect. Dis. 42(3), 389-391 (2006).
11. Livermore DM, Pearson A. Antibiotic resistance: location, location, location. Clin. Microbiol. Infect. 13(Suppl. 2), 7-16 (2007).
12. Schwaber Mi, De-Medina T, Carmeli Y. Epidemiological interpretation of antibiotic resistance studies - what are we missing? Nat. Rev. 2(12), 979-983 (2004).
13. Diekema DJ, Pfaller MA, Schmitz FJ et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 32(Suppl. 2), S114-S132 (2001).
14. Wertheim HF, Vos MC, Boelens HA et al. Low prevalence of methicillin-resistant Staphylococcus aureus (MRSA) at hospital admission in the Netherlands: the value of search and destroy and restrictive antibiotic use. J. hosp. Infect. 56(4), 321-325 (2004).
15. Grigoryan L, Haaijer-Rysjamp FM, Burgerhof JG et al. Self-medication with antimicrobial drugs in Europe. Emerging Infect. Dis. 12(3), 452-459 (2006).
16. Styers D, Sheehan DJ, Hogan P, Sahm DF. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureur. 2005 status in the United States. Ann. Clin. Microbiol. Antimicrob. 5, 2 (2006).
17. Maree CL, Daum RS, Boyle-Vavra S, Matayoshi K, Miller LG. Community-associated methicillin-resistant Stapbylococcus aureus isolates causing healthcare-associated infections. Emerging Infect, Dis. 13(2), 236-242 (2007).
18. Gonzalez BE, Rueda AM, Shelburne SA 3rd, Musher DM, Hamill RJ, Hulten KG. Community-associated strains of methicillin-resistant Staphylococcus aureus as the cause of healthcare-associated infection. Infect. Control Hosp. Epidemiol. 27 (10), 1051-1056 (2006).
19. Davis SL, Rybak MJ, Amjad M, Kaatz GW, McKinnon PS. Characteristics of patients with healthcare-associated infection due to SCCmec type IV methicillin-resistant Staphylococcus aureus. Infect. Control Hosp. Epidemiol. 27(10), 1025-1031 (2006).
20. Kaplan SL, Hulten KG, Gonzalez BE et al. Three-year surveillance of community-acquired Staphylocaccus auteus infections in children. Clin. Infect. Dis. 40(12), 1785-1791 (2005).
21. Chambers HF. Community-associated MRSA - resistance and virulence converge. N. Engl. J. Med. 352(14), 1485-1487 (2005).
22. Hota B, Ellenbogen C, Hayden MK, Aroutcheva A, Rice TW, Weinstein RA. Community-associated methicillin-resistant Staphylacoccus aureus skin and soft tissue infections at a public hospital: do public housing and incarceration amplify transmission? Arch. Intern. Med. 167(10), 1026-1033 (2007).
23. Groom AV, Woisey DH, Naimi TS et al. Community-acquired methicillin-resistant Staphylacoccus aureus in a rural American Indian community. JAMA 286(10), 1201-1205 (2001).
24. CDC. Outbreaks of community-associated methicillin-resistant Staphylococcus aureus skin infections - Los Angeles County, California, 2002-2003. MMWR Morb. Mortal. Wkly. Rep. 52(5), 88 (2003).
25. From the Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus - Minnesota and North Dakota, 1997-1999. JAMA 282(12), 1123-1125 (1999).
26. T resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 279(8), 593-598 (1998).
27. Kazakova SV, Hageman JC, Matava, M et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N. Engl. J. Med. 352 (5), 468-475 (2005).
28. Miller LG, Perdreau-Remington F, Bayer AS et al. Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylacoccus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation. Clin. Infect. Dis. 44(4), 471-482 (2007).
29. Frazee BW, Lynn J, Charlebois ED, Lambert L, Lowery D, Perdreau-Remington F. High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann. Emerg. Med. 45(3), 311-320 (2005).
30. King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann. Intern. Med. 144(5), 309-317 (2006).
31. Drew RH. Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections. Pharmacotherapy 27(2), 227-249 (2007).
32. Patel SM, Saravolatz LD. Monotherapy versus combination therapy. Med. Clin. North Am. 90 (6), 1183-1195 (2006).
33. Fernandez Guerrero ML, de Gorgolas M. Comparative activity of cloxacillin and vancomycin against methicillin-susceptible Staphylococcus aureus experimental endocarditis. J. Antimicrob. Chemother. 58(5), 1066-1069 (2006).
34. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin. Infect. Dis. 42 (Suppl. 1), S35-S39 (2006).
35. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin. Infect. Dis. 44(9), 1208-1215 (2007).
36. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin. Microbiol. 42(6), 2398-2402 (2004).
37. Scheetz; MH, Wunderink RG, Postelnick MJ, Naskin GA. Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia. Pharmacotherapy 26(4), 539-550 (2006).
38. Polk RE, Healy DP, Schwartz LB, Rock DT, Garson ML, Roller K. Vancomycin and the red-man syndrome: pharmacodynamics of histamine release. J. Infect. Dis. 157(3), 502-507 (1988).
39. Product information, Vancocin (2003).
40. Moise-Broder PA, Sakoulas G, Forrest A, Schentag JJ. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Anatimicrob. Agents Chemother. 51 (7), 2582-2586 (2007).
41. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin. Pharmacokinet. 43(13), 925-942 (2004).
42. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Intern. Med. 166(19), 2138-2144 (2006).
43. Sakoulas G, Moellering RC Jr, Eliopoulos GM. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin. Infect. Dis. 42 (Suppl. 1), S40-S50 (2006).
44. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr. Accessory gene regulator group II polymorphism in methicillin-resistant Shaphylococcus auirus is predictive of failure of vancomycin therapy. Clin. Infect. Dis. 38(12), 1700-1705 (2004).
45. Deresinski S. Counterpoint: Vancomycin and Staphylococcus aureus - an antibiotic enters obsolescence. Clin. Infect. Dis. 44(12), 1543-1548 (2007).
46. Mohr JF, Murray BE. Point: vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Shaphylococcus aureus. Clin Infect Dis. 44(12), 1536-1542 (2007).
47. Stein GE, Schooley S, Peloquin CA, Missavage A, Havlichek DH. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. J Antimicrob. Chemother. 60(4), 819-823 (2007).
48. Stevens DL, Ma Y, Saimi DB, McIndoo E, Wallace RJ, Bryant AE. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 195(2), 202-211 (2007).
49. MacGowan AP. Pharmacokinetic and pharmacodyciamic profile of linezolid in healthy volunteers and patients with Grampositive infections. J. Antimicrob. Chemother. 51(Suppl. 2), ii17-ii25 (2003).
50. Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin. Infect. Dis. 42(11), 1578-1583 (2006).
51. Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. Clin. Infect. Dis. 43(2), 180-187 (2006).
52. Bressler AM, Zimmer SM, Gilmore JL, Somani J. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect. Dis. 4(8), 528-531 (2004).
53. Javaheri M, Khurana RN, O'Hearn TM, Lai MM, Sadun AA. Linezolid-induced optic neuropathy: a mitochondrial disorder? Br. J. Qphthalmol. 91 (1), 111-115 (2007).
54. Apodaca AA, Rakita RM. Linezolid-induced lactic acidosis. N. Engl. J. Med. 348(1), 86-87 (2003).
55. De Vriese AS, Coster RV, Smet J et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin. Infect. Dis. 42(8), 1111-1117 (2006).
56. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. 49(6), 2260-2266 (2005).
57. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus autrus infections. Clin. Infect. Dis. 34 (11), 1481-1490 (2002).
58. Sharpe JN, Shively EH, Polk HC Jr., Clinical and economic outcomes of oral inezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Stapbylococcus aureus. Am. J. Surg. 189 (4), 425-428 (2005).
59. Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin. Infect. Dis. 32 (3), 402-412 (2001).
60. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin. Ther. 25(3), 980-992 (2003).
61. Wunderink RG, Reno J, Cammarata SK, Croos-Dabrera RV Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124 (5), 1789-1797 (2003).
62. Powers JH, Ross DB, Lin D, Soreth J. Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses. Chest 126 (1), 314-315 (2004).
63. Powers JH, Lin D, Ross D. FDA evaluation of antimicrobials: subgroup analysis. Chest 127(6), 2298-2301 (2005).
64. Lewis JS 2nd, Jorgensen JH. Inducible clindamycin resistance in staphylococci: should clinicians and microbiologists be concerned? Clin. Infect. Dis. 40(2), 280-285 (2005).
65. Feigin RD, Pickering LK, Anderson D, Keeney RE, Shackleford PG. Clindamycin treatment of osteomyefitis and septic arthritis in children. Pediatrics 55 (2), 213-223 (1975).
66. Rodriguez W, Ross S, Khan W, McKay D, Moskowitz P. Clindamycin in the treatment of osteomyelitis in children: a report of 29 cases. Am. J. Dis. Child, 131 (10), 1088-1093 (1977).
67. Wilson DH. Clindamycin in the treatment of soft tissue infections: a review of 15,019 patients. Br. J. Surg. 67(2), 93-96 (1980).
68. Geddes AM, Bridgwater FA, Williams DN, Oon J, Grimshaw GJ. Clinical and bacteriological studies with clindamycin. Br. Med J. 2 (5711), 703-704 (1970).
69. Geddes AM, Dwyer NS, Ball AP, Amos RS. Clindamycin in bone and joint infections. J. Antimicrob. Chemother. 3(5), 501-507 (1977).
70. Martinez-Aguitar G, Hammerman WA, Mason EO Jr, Kaplan SL. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr. Infect. Dis. J. 22(7), 593-598 (2003).
71. Stevens DL, Bisno AL, Chambers HF et al. Practice guidelines for the iagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis. 41 (10), 1373-1406 (2005).
72. Kaka AS, Rueda AM, Shelburne SA 3rd, Hulten K, Hamill RJ, Musher DM. Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 58(3), 680-683 (2006).
73. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann. Intern. Med. 117(5), 390-398 (1992).
74. Cenizal MJ, Skiest D, Luber S et al. Empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high MRSA prevalence: a prospective randomized trial. Antimicrob. Agents Chemother. 51(7), 2628-2630 (2007).
75. Szumowski JD, Cohen DE, Kanaya F, Mayer KH. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob. Agents Chemother. 51(2), 423-428 (2007).
76. Ruhe JJ, Monson T, Bradsher RW, Menon A. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin. Infect. Dis. 40(10), 1429-1434 (2005).
77. Ruhe JJ, Menon A. Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 51(9), 3298-3303 (2007).
78. Rose WE, Rybak MJ. Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy 26(8), 1099-1110 (2006).
79. Slover CM, Rodvold KA, Danziger LH. Tigecycline: a novel broad-spectrum antimicrobial. Ann. Pharmacother. 41(6), 965-972 (2007).
80. Bozdogan B, Esel D, Whitener C, Browne FA, Appelbaum PC. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J. Antimicrob. Chemother. 52(5), 864-868 (2003).
81. Sader HS, Jones RN, Stilwell MG, Dowzicky MJ, Fritsche TR. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn. Microbiol. Infect. Dis. 52(3), 181-186 (2005).
82. Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004). Diagn. Microbiol. Infect. Dis. 52(3), 195-201 (2005).
83. Bouchillon SK, Hoban DJ, Johnson BM, Johnson JL, Hsiung A, Dowzicky MJ. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagn. Microbiol. Infect. Dis. 52(3), 173-179 (2005).
84. LaPlante KL, Rybak MJ. Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline. Diagn. Microbiol. Infect. Dis. 50(2), 125-130 (2004).
85. Bouchillon SK, Johnson BM, Stevens T et al. Surveillance trends in the in vitro antibacterial activity of tigecycline in the years 2004 to 2006 - Tigecycline Evaluation Surveillance Trial (T.E.S.T.). In: Program and Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, CA, USA, September 27-30 (2006).
86. Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob. Agents Chemother. 49(1), 220-229 (2005).
87. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin. Infect. Dis. 41(Suppl. 5), S341-S353 (2005).
88. Conte JE Jr, Golden JA, Kelly MG, Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int. J. Antimicrob. Agents 25(6), 523-529 (2005).
89. Dukart G, Dartois N, Cooper D, Gandjini H, Elli-Grosse E. Integrated results of 2 phase 3 studies comparing tigecycline with levofloxacin in patients with community-acquired pneumonia. In: Program and Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, CA, USA, September 27-30 (2006).
90. Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J. Antimicrob. Chemother. 55(3), 283-288 (2005).
91. Lamp KC, Rybak MJ, Bailey EM, Kaatz GW. In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob. Agents Chemother. 36(12), 2709-2714 (1992).
92. French GL. Bactericidal agents in the treatment of MRSA infections - the potential role of daptomycin. J. Antimicrob. Chemother. 58(6), 1107-1117 (2006).
93. Critchley IA, Blosser-Middleton RS, Jones ME, Thornsberry C, Sahm DF, Karlowsky JA. Baseline study to determine in vitro activities of daptomycin against Gram-positive pathogens isolated in the United States in 2000-2001. Antimicrob. Agents Chemother. 47(5), 1689-1693 (2003).
94. Critchley IA, Draghi DC, Sahm DF, Thornsberry C, Jones ME, Karlowsky JA. Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001. J. Antimicrob. Chemother. 51(3), 639-649 (2003).
95. Tsuji B, Rybak M, Cheung C, Amjad M. Activity of daptomycin (DP), clindamycin (CL), linezolid (LZ), teicoplanin (TE), trimethoprim-sulfamethoxazole (T/S) and vancomycin (VN) against community (CA) and hospital-associated (HA) methicillin-resistant Staphylococcus aureus. In: Program and Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, DC, USA, December 16-19 (2005)
96. Cui L, Tominaga E, Neoh HM, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50(3), 1079-1082 (2006).
97. Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC Jr, Eliopoulos GM. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob. Agents Chemother. 50(4), 1581-1585 (2006).
98. Hayden MK, Rezai K, Hayes RA, Lolans K, Quinn JP, Weinstein RA. Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 43(10), 5285-5287 (2005).
99. Vikram HR, Havill NL, Koeth LM, Boyce JM. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin. J. Clin. Microbiol. 43(10), 5384-5387 (2005).
100. Hirschwerk D, Ginocchio CC, Bythrow M, Condon S. Diminished susceptibility to daptomycin accompanied by clinical failure in a patient with methicillin-resistant Staphylococcus aureus bacteremia. Infect. Control Hosp. Epidemiol. 27(3), 315-317 (2006).
101. Cottagnoud P, Pfister M, Acosta F et al. Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. Antimicrob. Agents Chemother. 48(10), 3928-3933 (2004).
102. Kazory A, Dibadj K, Weiner ID. Rhabdomyolysis and acute renal failure in a patient treated with daptomycin. J. Antimicrob. Chemother. 57(3), 578-579 (2006).
103. Papadopoulos S, Ball AM, Liewer SE, Martin CA, Winstead PS, Murphy BS. Rhabdomyolysis during therapy with daptomycin. Clin. Infect. Dis. 42(12), e108-e110 (2006).
104. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin. Infect. Dis. 38(12), 1673-1681 (2004).
105. Fowler VG Jr, Boucher HW, Corey GR et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355(7), 653-665 (2006).
106. Falagas ME, Giannopoulou KP, Ntziora F, Papagelopoulos PJ. Daptomycin for treatment of patients with bone and joint infections: a systematic review of the clinical evidence. Int. J. Antimicrob. Agents 30(3), 202-209 (2007).
107. Rao N, Regalla DM. Uncertain efficacy of daptomycin for prosthetic joint infections: a prospective case series. Clin. Orthop. Relat. Res. 451, 34-37 (2006).
108. Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J. Infect. Dis. 191(12), 2149-2152 (2005).
109. Pope SD, Roecker AM. Dalbavancin: a novel lipoglycopeptide antibacterial. Pharmacotherapy 26(7), 908-918 (2006).
110. Leighton A, Gottlieb AB, Dorr MB et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob. Agents Chemother. 48(3), 940-945 (2004).
111. Streit JM, Fritsche TR, Sader HS, Jones RN. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn. Microbiol. Infect. Dis. 48(2), 137-143 (2004).
112. Streit JM, Sader HS, Fritsche TR, Jones RN. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. Diagn. Microbiol. Infect. Dis. 53(4), 307-310 (2005).
113. Biedenbach DJ, Ross JE, Fritsche TR, Sader HS, Jones RN. Activity of dalbavancin tested against Staphylococcus spp. and β-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States. J. Clin. Microbiol. 45(3), 998-1004 (2007).
114. Flamm R, Draghi D, Jones M, Thornsberry C, Sahm DF. Dalbavancin demonstrates a low potential for in vitro selection of resistance in staphylococci. In: Program and Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington DC, USA, December 16-19 (2005)
115. Andes D, Craig WA. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob. Agents Chemother. 51(5), 1633-1642 (2007).
116. Seltzer E, Dorr MB, Goldstein BP, Perry M, Dowell JA, Henkel T. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin. Infect. Dis. 37(10), 1298-1303 (2003).
117. Jauregui LE, Babazadeh S, Seltzer E et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin. Infect. Dis. 41(10), 1407-1415 (2005).
118. Raad I, Darouiche R, Vazquez J et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin. Infect. Dis. 40(3), 374-380 (2005).
119. Hancock RE. Mechanisms of action of newer antibiotics for Gram-positive pathogens. Lancet Infect. Dis. 5(4), 209-218 (2005).
120. Blosser R, Loutit J, Porter S, Flamm R, Sahm D. Oritavancin demonstrates potent in vitro activity against clinically relevant isolates of staphylococci. In: Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, IL, USA, September 14-17 (2003).
121. Boylan CJ, Campanale K, Iversen PW, Phillips DL, Zeckel ML, Parr TR Jr. Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection. Antimicrob. Agents Chemother. 47(5), 1700-1706 (2003).
122. Mercier RC, Stumpo C, Rybak MJ. Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium. J. Antimicrob. Chemother. 50(1), 19-24 (2002).
123. Zhanel GG, Kirkpatrick ID, Hoban DJ, Kabani AM, Karlowsky JA. Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus. Antimicrob. Agents Chemother. 42(9), 2427-2430 (1998).
124. Lehoux D, Arhin F, Fadil I et al. Oritavancin demonstrates rapid and sustained bactericidal activity in the rat granuloma pouch model of Staphylococcus aureus infection. In: Program and Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, CA, USA, December 16-19 (2006).
125. Fetterly GJ, Ong CM, Bhavnani SM et al. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Antimicrob. Agents Chemother. 49(1), 148-152 (2005).
126. Wasilewski M, Disch D, McGill J, Harris H, O'Riordan W, Zeckel M. Equivalence of shorter course therapy with oritavancin vs. vancomycin/ cephalexin in complicated skin/skin structure infections (cSSI). In: Programm and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, IL, USA, December 16-19 (2001).
127. Giamarellou H, O'Riordan W, Harris H, Owens S, Porter S, Loutit J. Phase III trial comparing 3-7 days of oritavancin vs 10-14 days of vancomycin/ cephalexin in the treatment of patients with complicated skin and skin structure infections (cSSSI). In: Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, IL, USA, September 14-17 (2003).
128. Higgins DL, Chang R, Debabov DV et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49(3), 1127-1134 (2005).
129. Hegde SS, Reyes N, Wiens T et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against Gram-positive bacteria. Antimicrob. Agents Chemother. 48(8), 3043-3050 (2004).
130. Draghi D, Benton B, Cohen M et al. Baseline anti-staphylococcal profile of telvancin; results of the 2005 USA surveillance initiative. In: Program and Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, CA, USA (2005).
131. Leuthner KD, Cheung CM, Rybak MJ. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 58(2), 338-343 (2006).
132. Shaw JP, Seroogy J, Kaniga K, Higgins DL, Kitt M, Barriere S. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob. Agents Chemother. 49(1), 195-201 (2005).
133. Stryjewski ME, O'Riordan WD, Lau WK et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to Gram-positive bacteria. Clin. Infect. Dis. 40(11), 1601-1607 (2005).
134. Stryjewski ME, Chu VH, O'Riordan WD et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by Gram-positive bacteria: FAST 2 study. Antimicrob. Agents Chemother. 50(3), 862-867 (2006).
135. Jones ME. In-vitro profile of a new β-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus. Clin. Microbiol. Infect. 13(Suppl. 2), 17-24 (2007).
136. Chambers HF. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 49(3), 884-888 (2005).
137. Sahm D, Brown N, Draghi D et al. Profile of ceftobiprole activity staphylococci and S. Pneumoniae results of the 2005-2006 surveillance program. In: Program and Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, CA, USA, September 27-30 (2006).
138. Schmitt-Hoffmann A, Nyman L, Roos B et al. Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob. Agents Chemother. 48(7), 2576-2580 (2004).
139. Noel G, Strauss R, Pypstram R. Successful treatment of complicated skin infections due to staphylococci, including methicillin-resistant Staphylococcus aureus (MRSA) with ceftobiprole. In: Program and Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, CA, USA, September 27-30 (2006).
140. Naimi TS, LeDell KH, Como-Sabetti K et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 290(22), 2976-2984 (2003).
141. Charlebois ED, Perdreau-Remington F, Kreiswirth B et al. Origins of community strains of methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 39(1), 47-54 (2004).
142. Graham PL 3rd, Lin SX, Larson EL. A US population-based survey of Staphylococcus aureus colonization. Ann. Intern. Med. 144(5), 318-325 (2006).
143. Fridkin SK, Hageman JC, Morrison M et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N. Engl. J. Med. 352(14), 1436-1444 (2005).
144. Moran GJ, Krishnadasan A, Gorwitz RJ et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 355(7), 666-674 (2006).